Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest American Association for the Study of Liver Diseases Stories

2011-10-20 08:14:00

ALEXANDRIA, Va., Oct. 20, 2011 /PRNewswire/ -- AASLD President's Press Conference Saturday, November 5, 2011 - 4:00-5:00 pm Room 2011, Moscone West Convention Center San Francisco, California AASLD President T. Jake Liang, MD, will host a press conference on the first full day of presentations at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases. Dr. Liang will highlight individual studies and themes from the 2300...

2011-10-03 06:15:00

HOERSHOLM, Denmark, and SAN DIEGO, Oct. 3, 2011 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases...

2011-09-28 07:11:00

ARLINGTON, Va., Sept. 28, 2011 /PRNewswire/ -- On Monday, September 26, 2011, the American Association for the Study of Liver Diseases published online at its journal Hepatology's website (http://onlinelibrary.wiley.com/doi/10.1002/hep.24641/full) an update to its practice guidelines for hepatitis C - "An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases." AASLD is the premiere...

2011-09-15 09:12:00

SAN FRANCISCO, Sept. 15, 2011 /PRNewswire/ -- The Liver Meeting® is the premier meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies. Approximately 10 percent of Americans have some form of liver disease, but fortunately, the research community has made great strides in recent years in developing new treatments for patients. At this year's meeting, 2312...

2011-05-12 14:53:00

ALEXANDRIA, Va., May 12, 2011 /PRNewswire/ -- The American Association for the Study of Liver Diseases (AASLD) welcomes the United States Department of Health and Human Services' (HHS) report Combating the Silent Epidemic: US Department of Health and Human Services Action Plan for the Prevention, Care and Treatment of Viral Hepatitis. The plan was developed by an interagency working group in collaboration with professional societies, community-based organizations, and other members of the...

2010-11-01 08:35:00

BOSTON, Nov. 1, 2010 /PRNewswire/ -- Dr. Howard Koh, the 14th Assistant Secretary for Health for the U.S. Department of Health and Human Services (HHS), described the steps the U.S. administration is taking in response to the recent Institute of Medicine (IOM) report on viral hepatitis in his 2010 President's Choice Lecture at The Liver Meeting®, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). Dr. Koh formed and led a U.S. Department...

2010-10-01 08:55:00

CAMBRIDGE, Mass., Oct. 1 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that three abstracts have been accepted for presentation at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, October 29-November 2, 2010 in Boston, Massachusetts). The abstracts being presented are on three of the...

2010-09-27 09:00:00

WASHINGTON, Sept. 27 /PRNewswire/ -- The American Association for the Study of Liver Diseases (AASLD) and the Trust for America's Health (TFAH) issued a new report today calling for action to be taken to transform how the country deals with viral hepatitis - to help identify millions of Americans who know they are living with chronic forms of hepatitis B and C and to assure access to treatment for all who need it, to prevent even more Americans from becoming infected. "This report is a...

2010-09-20 15:44:00

ALEXANDRIA, Va., Sept 20 /PRNewswire/ -- The Liver Meeting® is the premier meeting in the science and practice of hepatology, including the latest findings on new drugs, novel treatments, and the results from pilot and multicenter studies. Approximately 10 percent of Americans have some form of liver disease, and the diseases strike disproportionately among certain populations but mostly regardless of lifestyle choices. There are now numerous treatments for both...

2009-11-03 07:15:00

BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- Pharmasset, Inc (Nasdaq: VRUS) and InterMune, Inc. (Nasdaq: ITMN) today announced results from all patient cohorts of the INFORM-1 trial, an innovative Phase 1 study of two direct-acting antiviral (DAA) compounds administered without interferon or ribavirin for the treatment of patients chronically infected with the hepatitis C virus (HCV).(i) The study, conducted by Roche as part of its collaborations with InterMune and Pharmasset, combined the...